

**WEST** **Generate Collection**

L17: Entry 4 of 5

File: DWPI

Apr 10, 2001

DERWENT-ACC-NO: 1999-458251

DERWENT-WEEK: 200122

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: Synergistic antitumor composition for treating e.g.  
leukemias, carcinomas, melanomas and mixed types of neoplasias

INVENTOR: GRANDI, M; SOLA, F

PRIORITY-DATA: 1997GB-0027524 (December 31, 1997)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6214860 B1	April 10, 2001	N/A	000	A61K031/40
WO 9934796 A1	July 15, 1999	E	035	A61K031/40
EP 975341 A1	February 2, 2000	E	000	A61K031/40

INT-CL (IPC): A61K 31/40

ABSTRACTED-PUB-NO: US 6214860B

## BASIC-ABSTRACT:

NOVELTY - Synergistic antitumor composition comprises a ureido compound (I) and an antineoplastic agent.

DETAILED DESCRIPTION - A synergistic antitumor composition comprises:

(a) a ureido compound of formula (I) or its salt: and

(b) an antineoplastic agent selected from an antineoplastic vinca alkaloid, antibiotic, antimetabolite, platinum coordination complex, taxane compound, ceramide compound, distamycin compound, epidophyllotoxin compound and topoisomerase I inhibitor.

m, n = 1-3;

R = naphthyl substituted by 1-3 sulfonic groups.

INDEPENDENT CLAIMS are included for the following:

(1) products comprising synergistic amounts of (a) and (b) as a combined preparation for simultaneous, separate or sequential use in antitumor therapy; and

(2) use of the composition for reducing side effects caused by antineoplastic therapy.

ACTIVITY - Antitumor.

Antitumor activity of combinations of 7,7'-(carbonyl-bis(imino-N-methyl-4,2-pyrrole)carbonylimino(N-methyl-4,2-pyrrole)carbonylimino)bis(-1,3-naphthalendisulfonic acid)tetrasodium salt (Ia) with 5 cytotoxic agents was determined in-vivo in mice implanted with M5076 murine reticulosarcoma cells. (Ia) was administered intraperitoneally 2 hours prior to cytotoxic drugs administered intravenously starting treatment 24 hours after tumor implant. Treatments were performed on days 1, 4, 7 and 11. The cytotoxic agents administered were: paclitaxel, cisplatin, etoposide, irinotecan and 9-aminocamptothecin. Treatment with (Ia) and each of the cytotoxic drugs produced greater inhibition of tumor growth and increased tumor growth delay compared to treatment with 1 drug alone. Combinations of (Ia) with etoposide and irinotecan produced a significant increase in survival time. No increase in toxicity was observed.

USE - For treating neoplastic disease states, including leukemias, carcinomas, melanomas and mixed types of neoplasias, e.g. carcinosarcoma, lymphoid tissue type, follicular reticulum, cell sarcoma and Hodgkins disease.

ADVANTAGE - Lower dosages of the antineoplastic agent may be used, reducing toxic side effects.

ABSTRACTED-PUB-NO:

WO 9934796A EQUIVALENT-ABSTRACTS:

NOVELTY - Synergistic antitumor composition comprises a ureido compound (I) and an antineoplastic agent.

DETAILED DESCRIPTION - A synergistic antitumor composition comprises:

(a) a ureido compound of formula (I) or its salt: and

(b) an antineoplastic agent selected from an antineoplastic vinca alkaloid, antibiotic, antimetabolite, platinum coordination complex, taxane compound, ceramide compound, distamycin compound, epidophyllotoxin compound and topoisomerase I inhibitor.

m, n = 1-3;

R = naphthyl substituted by 1-3 sulfonic groups.

INDEPENDENT CLAIMS are included for the following:

(1) products comprising synergistic amounts of (a) and (b) as a combined preparation for simultaneous, separate or sequential use in antitumor therapy; and

(2) use of the composition for reducing side effects caused by antineoplastic therapy.

ACTIVITY - Antitumor.

Antitumor activity of combinations of 7,7'-(carbonyl-bis(imino-N methyl-4,2 pyrrolicarbonyl-imino(N-methyl-4,2 pyrrole)carbonylimino))bis(-1,3-naphthalendisulfonic acid)tetrasodium salt (Ia) with 5 cytotoxic agents was determined in-vivo in mice implanted with M5076 murine reticulosarcoma cells. (Ia) was administered intraperitoneally 2 hours prior to cytotoxic drugs administered intravenously starting treatment 24 hours after tumor implant. Treatments were performed on days 1, 4, 7 and 11. The cytotoxic agents administered were: paclitaxel, cisplatin, etoposide, irinotecan and 9-aminocamptothecin. Treatment with (Ia) and each of the cytotoxic drugs produced greater inhibition of tumor growth and increased tumor growth delay compared to treatment with 1 drug alone. Combinations of (Ia) with etoposide and irinotecan produced a significant increase in survival time. No increase in toxicity was observed.

USE - For treating neoplastic disease states, including leukemias, carcinomas, melanomas and mixed types of neoplasias, e.g. carcinosarcoma, lymphoid tissue type, follicular reticulum, cell sarcoma and Hodgkins disease.

ADVANTAGE - Lower dosages of the antineoplastic agent may be used, reducing toxic side effects.